Atacicept

Atacicept
Mass / length primary structure	approx. 71 kDa
Identifier
External IDs	CAS number : 845264-92-8;
Drug information
ATC code	L04 AB
Drug class	Immunosuppressants

Atacicept is an experimental drug being developed to treat autoimmune diseases. Atacicept is a recombinantly produced fusion protein and binds the inflammation- causing cytokines BAFF and APRIL , which regulate the maturation and survival of B-lymphocytes .

structure

Atacicept (other name: TACI-Ig) consists of the extracellular part of the TACI receptor (TACI, an abbreviation for Transmembrane Activator and CAML-interactor ) that is linked to the Fc fragment of human immunoglobulin G. Atacicept has a molar mass of approximately 71 k Da .

Mechanism of action

The TACI receptor is located on the B lymphocytes ( short : B cells). Certain cytokines, namely BAFF ( B cell activating factor ) and APRIL ( A Proliferation-Inducing Ligand ) bind to the TACI receptors and promote the maturation, development and survival of the B lymphocytes. Atacicept binds BAFF and APRIL so that they can no longer act on the B lymphocytes. B-lymphocytes are involved in the development of certain autoimmune diseases through the formation of autoantibodies .

Atacicept is not approved, but is currently being investigated in studies for various autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis . Developments for multiple sclerosis and optic neuritis were discontinued after increased disease activity was observed in a phase II study.

literature

Gatto B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells . Curr Opin Investig Drugs . 2008; 9: 1216-27, PMID 18951301 .

Web links

Study registry for atacicept. US National Institutes of Health :; Retrieved October 10, 2010.

Individual evidence

↑ ^a ^b ABDA drugs. Database at DIMDI .
↑ Recommended INN: List 57 . In: WHO Drug Information , Vol. 21 (2007) No. 1, p. 58.
^ Susanne Heinzl: New Antibodies and Peroralia in Sight . In: Pharmazeutische Zeitung , No. 25, 2009, pharmische-zeitung.de
↑ Zymogenetics says Merck Serono discontinues MS trials . Reuters, August 28, 2009; Retrieved October 10, 2010.

[abda-1] ABDA drugs. Database at DIMDI .

[2] Recommended INN: List 57 . In: WHO Drug Information , Vol. 21 (2007) No. 1, p. 58.

[3] Susanne Heinzl: New Antibodies and Peroralia in Sight . In: Pharmazeutische Zeitung , No. 25, 2009, pharmische-zeitung.de

[4] Zymogenetics says Merck Serono discontinues MS trials . Reuters, August 28, 2009; Retrieved October 10, 2010.